Excerpted from FHCi’s newest publication, “Long-term Homoeoprophylaxis Study in Children in North America: Part One and Part Two.”
Now available for purchase: $15.95
Table 2.1.b. below shows reported adverse events* compared to total number of dosing series per individual nosode/remedy. As per table 2.1.a. in a total of 9,333 individual doses given, there were no adverse events reported in both Unvaccinated and Previously Vaccinated cohorts.
*Adverse events as defined by the National Institute of Health guidelines for research on human subject is defined as a death, life-threatening adverse drug or device experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent disability/incapacity, or a congenital anomaly/birth defectii.
ii (1999). Guidance on reporting adverse events to institutional review boards for nih-supported multicenter clinical trials. National Institute of Health. US. https://grants.nih.gov/grants/guide/notice-files/not99-107.html (Last viewed 4 October 2019).
